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Abstract
Backgroud: Accumulation of single nucleotide polymorphisms (SNPs) in the displacement loop (D-loop) of
mitochondrial DNA (mtDNA) has been described for different types of cancers and might be associated with
cancer risk and disease outcome. We used a population-based series of esophageal squamous cell carcinoma
(ESCC) patients for investigating the prediction power of SNPs in mitochondrial D-loop.
Methods: The D-loop region of mtDNA was sequenced for 60 ESCC patients recorded in the Fourth Hospital of
Hebei Medical University between 2003 and 2004. The 5 year survival curve were calculated with the Kaplan-Meier
method and compared by the log-rank test at each SNP site, a multivariate survival analysis was also performed
with the Cox proportional hazards method.
Results: The SNP sites of nucleotides 16274G/A, 16278C/T and 16399A/G were identified for prediction of post-
operational survival by the log-rank test. In an overall multivariate analysis, the 16278 and 16399 alleles were
identified as independent predictors of ESCC outcome. The length of survival of patients with the minor allele
16278T genotype was significantly shorter than that of patients with 16278C at the 16278 site (relative risk, 3.001;
95% CI, 1.029 - 8.756; p = 0.044). The length of survival of patients with the minor allele 16399G genotype was
significantly shorter than that of patients with the more frequent allele 16399A at the 16399 site in ESCC patients
(relative risk, 3.483; 95% CI, 1.068 - 11.359; p = 0.039).
Conclusion: Genetic polymorphisms in the D-loop are independent prognostic markers for patients with ESCC.
Accordingly, the analysis of genetic polymorphisms in the mitochondrial D-loop can help identify patient
subgroups at high risk of a poor disease outcome.
Background
Esophageal cancer is one of the commonest cancers in the
population of northern central China with an age-standar-
dized annual incidence rate > 125/100,000 [1]. Cumulative
mortality attributed to esophageal cancer is approximately
20% for women and 25% for men [2]. The prognosis of
esophageal cancer remains poor, despite improved diagno-
sis and therapeutic strategies, mostly because of its aggres-
sive nature. The performance status, the TNM stage, and
lymph node metastases seem to be the predictive factors
of esophageal cancer; some molecular factors, such as p53
mutaion and NF-kappaB expression level, also show pre-
dictive power for esophageal cancer outcome [3].
The human mitochondrial genome is 16 kb in length
and is a closed-circular duplex molecule that contains
37 genes, including 2 ribosomal RNAs and a complete
set of 22 tRNAs [4]. mtDNA is believed to be more sus-
ceptible to DNA damage and acquires mutations at a
higher rate than nuclear DNA, because of the high levels
of reactive oxygen species (ROS), the lack of protective
histones, and limited capacity for DNA repair in the
mitochondria [5,6].
In cancers patients, sequence changes accumulated
extensively in the mitochondrial D-loop region, which is
important for regulating both replication and expression
of the mitochondrial genome, because it contains the
leading-strand origin of replication and the main
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single nucleotide polymorphisms (SNPs) in the D-loop
have been shown to be prognostic of cancer risk and
outcome, but their predictive values have not been fully
determined [11-14]. The D-loop contains a length of
1122 bps (nucleotide 16024-16569 and 1-576) refers to
mitochondria database (http://www.mitomap.org). In
this study, we sequenced a region of about 1 kb in the
mitochondrial D-loop from 60 patients with esophageal
squamous cell carcinoma (ESCC), the main pathological
type of esophageal cancer in China, to assess the rela-
tionships between germline SNPs of the D-loop with
cancer risk and gemline SNPs with disease outcome in
ESCC patients.
Methods
Tissue specimens and DNA extraction
Blood samples were collected at the Fourth Hospital of
Hebei University from 66 ESCC patients who underwent
esophageal cancer resection in the Department of Thor-
acic Surgery between 2003 and 2004. The patients were
selected when they received endoscopy examination and
specimen were confirmed as ESCC by pathologist. All
the patients comes from the Hebei Province of China a
high risk area of ESCC. The tumor-free controls as
determined per endoscopy, radiograph, and blood exam-
ination, were randomly selected from the same area.
Both patients and controls contain 42 males and 24
females with the mean age of 59.78 ± 8.32 in ESCC
patients and 60.84 ± 8.77 in controls. Genomic DNA
was extracted immediately with a Wizard Genomic
DNA extraction kit (Promega, Madison, WI) from blood
samples. The study was approved by the Human Tissue
Research Committee of the Fourth Hospital of Hebei
M e d i c a lU n i v e r s i t y .A l lp a t i e n t sp r o v i d e dw r i t t e n
informed consent for the collection of samples and sub-
sequent analysis.
PCR amplification and sequence analysis
The forward primer 5’-CCCCATGCTTACAAGCA
AGT-3’ (nucleotide 16190-16209) and reverse primer 5’-
GCTTTGAGGAGGTAAGCTAC-3’ (nucleotide 602-
583) were used for amplification of a 982 bp product
from mtDNA D-Loop region as described previously
[15]. PCR was performed according to the protocol of
PCR Master Mix Kit (Promega, Madison, WI) and puri-
fied prior to sequencing. Cycle sequencing was carried
out with the Dye Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystem, Foster City, CA) and
the products were then separated on the ABIPRISM
Genetic Analyzer 3100 (Applied Biosystem). Polymorph-
isms were confirmed by repeated analyses from both
strands. SNPs were identified directly from blood
mitochondria.
Statistical analysis
The c
2 test was used to analyze dichotomous values,
such as the presence or absence of an individual SNP
between ESCC patients and healthy controls. The survi-
val curve was calculated using the Kaplan-Meier
method, and compared with the log-rank test. Multivari-
ate survival analysis was performed using a Cox propor-
tional hazards model. All of the statistical analysis was
done with the SPSS 11.5 software package (SPSS Com-
pany, Chicago, IL). A p value of < 0.05 was considered
statistically significant.
Results
A total of 66 patients were enrolled in this study. Six of
these patients were lost to follow-up. A review was con-
ducted every six months over a five-year period. Those
patients lost to follow-up during this time period were
as follows: 1 patient in Year 2; 1 patient in Year 3;
3 patients in Year 4; and, 1 patient in Year 5. Sixty
patients shared the same performance status (ECOG
Score: Zero). Those analyzed included: 12 patients at
Stage I; 33 patients at Stage II, and 15 patients at Stage
III. Thirty-six patients died during follow-up. None of
these patients had received any adjuvant chemotherapy
or radiation therapy after ESCC resection. Data for the
5 year follow-up period were analysed with clinical char-
acteristics using the Kaplan-Meier method and were
compared by the log-rank test. Sex, age and local lym-
phatic metastasis were not statistically significant predic-
tors of the length of post-operational survival, but TNM
stage was correlated with survival in these patients
(Table 1). As expected, patients at different stages had
different 5 year survival rates: stage I, 75%, stage II,
Table 1 Univariate analysis of clinical characteristics
associated with post-operational survival in ESCC
patients
Characteristics No. cases 5 years survival rate (%) p value
Gender 0.129
Male 37 35.10
Female 23 47.80
Age (years) 0.282
≤ 55 17 23.50
> 55 43 46.50
TNM classification
a 0.012
I1 2 7 5
II 33 36.40
III 15 20
Lymphatic metastases 0.418
Yes 12 33.30
No 48 41.70
aThe survival in each stage was compared as I versus II, I versus III and
II versus III
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Page 2 of 536.4% and stage III, 20%. The survival length distribu-
tion between any two stages was significantly different
(p < 0.05) by the log-rank test. These data demonstrated
that TNM stage is a good predictor of ESCC outcome.
SNPs in reference to GenBank accession AC_000021
were detected in 88 sites of the 982-bp mitochondria
D-Loop region from blood samples [see Additional file 1],
The sequence chromatograms show a clear single peak at
each nucleotide position, indicating that mitochondria in
ESCC individuals were homoplasmic. At first, we com-
pared the distribution of germline SNPs at each site
between ESCC and control patients to identify any link
between an SNP and cancer risk; no association with
ESCC cancer risk was detected in any SNP in the D-loop
at p < 0.05 levels. We assessed the relationships between
these SNPs and post-operational survival of these ESCC
patients.
The relationship between mtDNA genotype and survi-
val was compared subsequently, the ESCC patients were
divided into two groups on the basis of their genotype
at each SNP site, the post-operational survival curve was
plotted using the Kaplan-Meier method for all ESCC
patients at these sites. A dramatic difference in survival
rate appeared at 16274, 16278 (refers to rs41458645 in
NCBI SNP database, http://www.ncbi.nlm.nih.gov/snp/)
and 16399 alleles by the log-rank test (Figure 1). The 3
SNPs were previously identified in mitochondria data-
base (http://www.mitomap.org). The frequent allele
16274G, and the rare alleles 16278T and 16399G were
associated with a shorter period of survival, with p =
0.0431, 0.0064 and 0.0028, respectively (Figure 1A, B
and 1C). We performed multivariate analysis with Cox
proportional hazards model including the factors of
three SNPs and TNM stage. We coded G as 0 and A as
1 at 16274 position, C as 0 and T as 1 at 16278, A as 0
and G as 1 at 16399. We also coded I of TNM stage as
0, II as 1 and III as 2. As shown in Table 2, the 16278
and 16399 alleles were identified as independent predic-
tors for ESCC outcome. The length of survival for
patients with the rare allele 16278T genotype was signif-
icantly shorter than that for patients with the frequent
allele 16278C (relative risk, 3.001; 95% CI, 1.029 - 8.756;
p = 0.044) at the 16278 site. The same was seen for the
rare allele 16399G genotype when compared with
matched alleles 16399A at the 16399 site in ESCC
patients (relative risk, 3.483; 95% CI, 1.068 - 11.359; p =
0.039) (Table 2). These data demonstrated the strong
prediction power of 16278C/T and 16399A/G on out-
come for ESCC patients.
Discussion
Selected SNPs in the D-loop region have been examined
for the ability to predict cancer risk in other types of
tumour [11-14]. The present study has extended those
analyses to determine the cancer risk and the post-
operational survival-associated germline SNPs in a con-
tinuous sequence of mtDNA between nucleotides 16190
and 583 in ESCC patients. Three SNPs, 16274G/A,
Figure 1 Survival curve according to the nucleotide at position
(A) 16274, (B) 16278 and (C) 16399 in D-loop of ESCC patients.
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ciation with post-operational survival at statistically sig-
nificant levels by the log-rank test. Multivariate survival
analysis identified 16278C/T and 16399A/G to be inde-
pendent prediction markers for ESCC outcome.
We suggest for the first time that SNPs in the D-loop is
a prognostic factor in ESCC patients. The relative risk
(RR) of death in patients was significantly higher (16278C
versus 16278T, RR, 3.001; 95% CI, 1.029 - 8.756; p =
0.044. 16399A versus 16399G, RR, 3.483; 95% CI, 1.068 -
11.359; p = 0.039). Nucleotides 16278 and 16399 are
located in hypervariable segment 1 (HV1), which is asso-
ciated with high rates of mutation [16], but the functional
significance of these SNPs in HV1 is not known. Minor
alleles of 16278T and 16399G are associated with drama-
tically shorter period of postoperative survival; the survi-
val curve decreased rapidly in patients carrying these
alleles (Figure 1). We compared the distribution fre-
quency of these two SNPs between ESCC patients and
normal controls; among 60 age-matched controls, only
one carried the 16278T allele and none carried the
16399G allele. These two minor alleles appear to be cor-
related with ESCC risk, butam u c hl a r g e rs a m p l es i z e
will be needed to obtain a statistically significant differ-
ence of distribution frequency for these alleles between
ESCC patients and controls. It is very interesting if a
nucleotide substitution can render an individual suscepti-
ble to a tumour but subsequently modulates prognosis of
that tumour. The 5 year survival rate displays a trend for
distinction on the basis of sex (35.1% male versus 47.8%
female), age (46.5% older than 55 versus 23.5% younger
than 55) and lymphatic metastasis (33.3% yes versus
41.7% no). The prediction value of these factors need to
be investigated by further study.
The D-loop region of mtDNA is important for regula-
tion of mitochondrial genome replication and expression.
SNPs in this region might affect mtDNA replication and
lead to alteration of the electron transport chain, which is
responsible for the release of highly reactive oxygen spe-
cies (ROS) and could contribute to nuclear genome
damage as well as cancer initiation and promotion
[17-19]. These three SNPs may altered transcription of
mitochondrial genome, and that the production of ROS
is enhanced when the mitochondrial transcription is
altered [20], these ROS-mediated mechanism may accel-
erate the tumor development.
In conclusion, SNPs in the D-loop were found to be
independent prognostic markers for ESCC outcome.
The analysis of genetic polymorphisms in the D-loop
might help to identify patient subgroups at high risk for
a disease outcome, thereby helping to refine therapeutic
decisions in ESCC cancers.
Additional material
Additional file 1: Distribution of 88 SNPs in 66 ESCC patients and
controls. The data provided represent all the SNPs identified in the ESCC
patients and controls.
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